LifeStance Health Group, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
LFST$14.56-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders' Equity
| Common Stock · AdditionalPaid-in · Accumulated · Total Stockholders' | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balances at June 30, 2026 | 382,022 | $3,820 | $2,244,099 | $(770,771) | $1,477,148 |
| Net income | — | — | — | 22,385 | 22,385 |
| Issuance of common stock upon vesting of restricted stock units | 169 | 2 | (507) | — | (505) |
| Repurchases of common stock | (2,000) | (20) | (24,785) | — | (24,805) |
| Stock-based compensation expense | — | — | 18,168 | — | 18,168 |
| Balances at September 30, 2026 | 380,191 | $3,802 | $2,236,975 | $(748,386) | $1,492,391 |
| Common Stock · AdditionalPaid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balances at June 30, 2025 | 389,077 | $3,891 | $2,291,056 | $345 | $(821,371) | $1,473,921 |
| Net income | — | — | — | — | 1,077 | 1,077 |
| Issuance of common stock upon vesting of restricted stock units | 116 | 1 | (210) | — | — | (209) |
| Forfeitures | (193) | (2) | 2 | — | — | — |
| Other comprehensive loss | — | — | — | (345) | — | (345) |
| Stock-based compensation expense | — | — | 18,297 | — | — | 18,297 |
| Balances at September 30, 2025 | 389,000 | $3,890 | $2,309,145 | $— | $(820,294) | $1,492,741 |
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
| Common Stock · AdditionalPaid-in · Accumulated · Total Stockholders' | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balances at December 31, 2025 | 388,318 | $3,883 | $2,325,758 | $(808,626) | $1,521,015 |
| Net income | — | — | — | 60,240 | 60,240 |
| Issuance of common stock upon vesting of restricted stock units | 6,987 | 70 | (24,989) | — | (24,919) |
| Forfeitures | (819) | (8) | 8 | — | — |
| Exercise of stock options | 705 | 7 | 5,361 | — | 5,368 |
| Repurchases of common stock | (15,000) | (150) | (122,280) | — | (122,430) |
| Stock-based compensation expense | — | — | 53,117 | — | 53,117 |
| Balances at September 30, 2026 | 380,191 | $3,802 | $2,236,975 | $(748,386) | $1,492,391 |
| Common Stock · AdditionalPaid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balances at December 31, 2024 | 382,735 | $3,827 | $2,259,818 | $929 | $(818,289) | $1,446,285 |
| Net loss | — | — | — | — | (2,005) | (2,005) |
| Issuance of common stock upon vesting of restricted stock units | 6,540 | 66 | (8,673) | — | — | (8,607) |
| Forfeitures | (275) | (3) | 3 | — | — | — |
| Other comprehensive loss | — | — | — | (929) | — | (929) |
| Stock-based compensation expense | — | — | 57,997 | — | — | 57,997 |
| Balances at September 30, 2025 | 389,000 | $3,890 | $2,309,145 | $— | $(820,294) | $1,492,741 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.